A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Nab-Paclitaxel and Gemcitabine in Subjects With Previously Untreated Stage IV Pancreatic Cancer

Memorial Sloan-Kettering Cancer Center, New York

Duke University Medical Center, Durham

Greenville Health System, Clinical Research Unit, Institute for Translational Oncology Research, Greenville

Northside Hospital, Inc. - GCS/Almex, Atlanta

Orlando Health, Inc., Orlando

Sarah Cannon Research Institute, Nashville

Cleveland Clinic, Cleveland

Oncology Hematology Care, Inc., Cincinnati

University of Michigan Health System, Ann Arbor

University of Wiscons in Hospi tal and Clinics, Madison

Allina Health, Virginia Piper Cancer Institute, Minneapolis

Washington University School of Medicine, St Louis

Peggy and Charles Stephenson Cancer Center, Oklahoma City

South Texas Accelerated Research Thereapeutics, LLC (START), San Antonio

Rocky Mountain Cancer Centers, Denver

Western Regional Medical Center, Inc., Goodyear

Comprehensive Cancer Centers ofNevada, Las Vegas

Ronald Reagan UCLA Medical Center, Drug Information Center, Department of Pharmaceutical Services, Los Angeles

Torrance Health Association Dba Torrance Memorial Physician Network/Cancer Care Associates, Redondo Beach

Pacific Shores Medical Group, Long Beach

St Jude Heritage Healthcare Virginia K. Crosson Cancer Center, Fullerton

CBCC Global Research, Inc. at Comprehensive Blood and Cancer Center, Bakersfield

Bend Memorial Clinic, Bend

Virginia Mason Medical Center, Seattle

Froedtert Hospital & Medical College of Wisconsin, Milwaukee

Beth Israel Deaconess Medical Center, Boston